NICE U-turn puts Janssen's Zytiga ahead of Sanofi's Jevtana in prostate cancer
This article was originally published in Scrip
Executive Summary
A revised patient access scheme and more information about the patients likely to benefit from Janssen Cilag's Zytiga (abiraterone) have persuaded NICE, the health technology appraisal body for England and Wales, to change its mind and recommend the drug for castration-resistant metastatic prostate cancer patients after one round of treatment with docetaxel.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.